Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Recruiting 4Completed 4Withdrawn 1Unknown 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Head & Neck 4

Conditions

Carcinoma, Non-Small-Cell Lung 18Carcinoma, Hepatocellular 11Stomach Neoplasms 10Esophageal Squamous Cell Carcinoma 10Squamous Cell Carcinoma of Head and Neck 9Lung Neoplasms 8Colorectal Neoplasms 8Rectal Neoplasms 5Advanced Solid Tumor 5Head and Neck Neoplasms 4Triple Negative Breast Neoplasms 3Esophageal Neoplasms 3Cholangiocarcinoma 3Urinary Bladder Neoplasms 2Small Cell Lung Carcinoma 2Neoplasm, Residual 2Nasopharyngeal Carcinoma 2Lymphoma 2Leukemia, Myeloid, Acute 2Colonic Neoplasms 2Biliary Tract Neoplasms 2Advanced Solid Tumour 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of External Auditory Canal 1Solid Tumor, Adult 1Solid Tumor 1Small Cell Lung Cancer Extensive Stage 1Simpson-Golabi-Behmel syndrome 1Sarcoma 1Renal Pelvic Carcinoma 1

Interventions

pembrolizumab 25Cisplatin 17Carboplatin 13Radiotherapy 12Cetuximab 9Blood Specimen Collection 9Docetaxel 8Paclitaxel 7Fluorouracil 7Drug Therapy 7toripalimab 6tislelizumab 4nimotuzumab 4atezolizumab 4Radiation 4Chemoradiotherapy 4fludarabine 3Surveys and Questionnaires 3Surgical Procedures, Operative 3Standard of Care 3Radiotherapy, Intensity-Modulated 3Cyclophosphamide 3Biopsy 3130-nm albumin-bound paclitaxel 3cemiplimab 2avelumab 2X-Rays 2Tocopherols 2Tiragolumab 2Therapeutics 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Head and Neck Neoplasms × tislelizumab × Clear all
NCT07601737 2026-05-22

Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2 Recruiting
182 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05526924 2026-03-04

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

University of Chicago

Phase 1 Recruiting
30 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05758389 2025-09-05

Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2 Recruiting
29 enrolled
Head & Neck

Head and Neck Neoplasms

NCT05595590 2022-10-27

Radiotherapy With Tislelizumab in Patients With Recurrent Head & Neck Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Recruiting
20 enrolled
Head & Neck

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡